AJP - Endocrinology and Metabolism, Vol 261, Issue 5 E642-E646, Copyright © 1991 by American Physiological Society

ARTICLES

Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems

P. Eggena, P. Willsey, N. Jamgotchian, L. Truckenbrod, M. S. Hu, J. D. Barrett, M. P. Eggena, K. Clegg, F. Nakhoul and D. B. Lee
Veterans Administration Medical Center, Sepulveda, California 91343.

In humans, blockade of the renin-angiotensin system with angiotensin converting-enzyme inhibitors (ANG CEI) prevents the rise in blood pressure associated with the administration of recombinant human erythropoietin (rhEPO). This study was conducted to determine whether rhEPO elevates blood pressure in normal Wistar rats and whether the renin-ANG system is affected. Groups of 10 rats each were given rhEPO, ANG CEI (enalapril), rhEPO + ANG CEI, or vehicle. Renin and/or renin substrate mRNA was measured in aortas, kidney, and heart; renin activity (PRA), inactive renin, and renin substrate were measured in plasma. rhEPO raised blood pressure in the normal rat without changing the plasma renin system. ANG CEI prevented this blood pressure rise. Renin-specific mRNA was increased by rhEPO in renal tissue, and renin substrate mRNA was significantly elevated in the kidney and aorta. mRNA for renin and renin substrate were not altered in the heart. In both aorta and kidney, a significant correlation was observed between renin substrate mRNA and blood pressure. The data indicate that rhEPO modulates specific tissue renin-ANG systems, which may contribute to blood pressure elevation.

This article has been cited by other articles:

				J. W. Fisher Erythropoietin: Physiology and Pharmacology Update Experimental Biology and Medicine, January 1, 2003; 228(1): 1 - 14. [Abstract] [Full Text] [PDF]

				P. Romsi, E. Ronka, K. Kiviluoma, V. Vainionpaa, J. Hirvonen, A. Mennander, M. Pokela, F. Biancari, J. Rimpilainen, and T. Juvonen Potential neuroprotective benefits of erythropoietin during experimental hypothermic circulatory arrest J. Thorac. Cardiovasc. Surg., October 1, 2002; 124(4): 714 - 723. [Abstract] [Full Text] [PDF]

				H. Schunkert and H.-W. Hense A heart price to pay for anaemia Nephrol. Dial. Transplant., March 1, 2001; 16(3): 445 - 448. [Full Text] [PDF]

				E. BROCHU, S. LACASSE-M, R. LARIVIÈRE, I. KINGMA, J. H. GROSE, and M. LEBEL Differential Effects of Endothelin-1 Antagonists on Erythropoietin-Induced Hypertension in Renal Failure J. Am. Soc. Nephrol., July 1, 1999; 10(7): 1440 - 1446. [Abstract] [Full Text]

				Z. Ni, X. Q. Wang, and N. D. Vaziri Nitric Oxide Metabolism in Erythropoietin-Induced Hypertension : Effect of Calcium Channel Blockade Hypertension, October 1, 1998; 32(4): 724 - 729. [Abstract] [Full Text] [PDF]

				K. Kamide, M. T. Hori, J.-H. Zhu, J. D. Barrett, P. Eggena, and M. L. Tuck Insulin-Mediated Growth in Aortic Smooth Muscle and the Vascular Renin-Angiotensin System Hypertension, September 1, 1998; 32(3): 482 - 487. [Abstract] [Full Text] [PDF]